NCT01585935View on ClinicalTrials.gov

Preventing Cholestasis Using SMOFLipid®

PHASE4CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

November 13, 2017

Conditions
CholestasisPsychomotor Disorders, Developmental
Interventions
DRUG

SMOFLIPID

target dose: 3g/kg/d

DRUG

INTRALIPID

target dose: 3g/kg/d

Trial Locations (1)

1090

Medical University Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT01585935 - Preventing Cholestasis Using SMOFLipid® | Biotech Hunter | Biotech Hunter